Wockhardt
Biosimilar developer, India. 3 development products across 3 molecules: epoetin alfa and zeta, insulin glargine, pegfilgrastim.
About Wockhardt
Wockhardt was one of the first Indian biosimilar makers. Its human insulin, Wosulin, launched in 2003, and its epoetin, Wepox, in 2001, both before the published permission lists begin. It holds the first insulin glargine permission in the published lists, from 2007, and permissions for pegfilgrastim and a new epoetin.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Epoetin alfa and zeta | Wockhardt epoetin | · | · | · | · | · | Feb 2023 | · | 1/7 |
| Insulin glargine | Wockhardt insulin glargine | · | · | · | · | · | Feb 2007 | · | 1/7 |
| Pegfilgrastim | Wockhardt pegfilgrastim | · | · | · | · | · | Feb 2015 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
In development
ClinicalTrials.gov lists one comparative trial sponsored by Wockhardt for one molecule: insulin lispro. Candidates without an approval yet in the seven markets: Wockhardt insulin lispro.
| Molecule | Candidate | Developer or sponsor | Reference product | Phase | Design | Registry status | Started | Primary completion | In the Atlas | Registry record |
|---|---|---|---|---|---|---|---|---|---|---|
| Insulin lispro | Wockhardt insulin lispro | Wockhardt | Humalog | Phase 3 | Comparative efficacy | Withdrawn | Feb 2012 | Mar 2013 | no approval in the seven markets | NCT01398670 |
Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.
Companies on the same molecules
Developers whose portfolios overlap most with Wockhardt, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOFeb 2007Wockhardt (INN only), insulin glargine
- CDSCOFeb 2015Wockhardt (INN only), pegfilgrastim
- CDSCOFeb 2023Wockhardt (INN only), epoetin alfa and zeta
Compare Wockhardt with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant